Your browser doesn't support javascript.
loading
The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal.
Malkin, Samuel J P; Carvalho, Davide; Costa, Catarina; Conde, Vasco; Hunt, Barnaby.
Affiliation
  • Malkin SJP; Ossian Health Economics and Communications GmbH, Bäumleingasse 20, 4051, Basel, Switzerland. malkin@ossianconsulting.com.
  • Carvalho D; Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar Universitário de S João, Faculty of Medicine and Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal.
  • Costa C; Novo Nordisk Portugal, Lda, Paço de Arcos, Portugal.
  • Conde V; Novo Nordisk Portugal, Lda, Paço de Arcos, Portugal.
  • Hunt B; Ossian Health Economics and Communications GmbH, Bäumleingasse 20, 4051, Basel, Switzerland.
Diabetol Metab Syndr ; 14(1): 32, 2022 Feb 14.
Article in En | MEDLINE | ID: mdl-35164855
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Health_economic_evaluation Aspects: Patient_preference Language: En Journal: Diabetol Metab Syndr Year: 2022 Document type: Article Affiliation country: Switzerland Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Health_economic_evaluation Aspects: Patient_preference Language: En Journal: Diabetol Metab Syndr Year: 2022 Document type: Article Affiliation country: Switzerland Country of publication: United kingdom